J. Kuball

发表

Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT

P. Ljungman, C. Chabannon, K. Mauff, 2021, Bone Marrow Transplantation.

γ9δ2T cell diversity and the receptor interface with tumor cells.

A. Heck, D. Olive, K. Lidke, 2020, The Journal of clinical investigation.

Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control

A. de Bruin, W. Scheper, R. Oostvogels, 2021, Frontiers in Immunology.

γδ T-cell receptors derived from breast cancer–infiltrating T lymphocytes mediate antitumor reactivity

Ralf, K. Heise, D. Chudakov, 2020 .

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

γ9δ2 T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3δ Repertoire of Healthy Adults

Z. Sebestyén, J. Kuball, D. Beringer, 2022, Frontiers in Immunology.

Cell-density independent increased lymphocyte production and loss rates post-autologous HSCT

M. V. van Zelm, J. Borghans, R. D. de Boer, 2021, eLife.

Cell-density independent increased lymphocyte production and loss rates post-autologous hematopoietic stem cell transplantation

M. V. van Zelm, J. Borghans, R. D. de Boer, 2020 .

Lymphocyte production and loss rates remain elevated post-autologous hematopoietic stem cell transplantation

M. V. van Zelm, J. Borghans, R. D. de Boer, 2020, medRxiv.

Uncovering the mode of action of engineered T cells in patient cancer organoids

Annelisa M Cornel, H. Clevers, A. Eggermont, 2022, Nature Biotechnology.

Redirecting (cid:1)(cid:2) T cells against cancer cells by transfer of a broadly tumor-reactive (cid:3)(cid:4) T-cell receptor

S. Strand, A. Martens, V. Marcu-Malina, 2011 .

Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust

L. E. van der Wagen, J. Kuball, A. van Rhenen, 2021, HemaSphere.

(cid:1) 9 and (cid:2) 2CDR3 domains regulate functional avidity of T cells harboring 2TCRs

R. Strong, A. Martens, W. Scheper, 2012 .

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers

J. Kuball, D. Beringer, Patricia Hernández-López, 2023, Frontiers in Immunology.

The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges

L. Schrier, A. Bruns, Z. Sebestyén, 2022, Viruses.

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

R. Hagedoorn, M. Heemskerk, J. Leusen, 2022, Oncoimmunology.

Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

A. Schulz, D. Niederwieser, M. Eyrich, 2021, Bone Marrow Transplantation.

Molecular Design of the Cαβ Interface Favors Specific Pairing of Introduced TCRαβ in Human T Cells1

P. Romero, C. Huber, M. Theobald, 2008, The Journal of Immunology.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

H. Inoko, M. Labopin, I. Yakoub-Agha, 2016, Blood.

Tumor-reactivity of δ2 negative γδT cells and the role of the γδT cell receptor

J. Kuball, D. Beringer, S. van Dooremalen, 2021, bioRxiv.

Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile

J. Janssen, G. Huls, C. de Haar, 2020, Bone Marrow Transplantation.

Serpin B9 controls tumor cell killing by CAR T cells

N. Bovenschen, M. Minnema, V. Peperzak, 2023, Journal for ImmunoTherapy of Cancer.

Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor.

M. V. van Buuren, S. Strand, A. Martens, 2008, Blood.

Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies

Z. Sebestyén, J. Kuball, D. Beringer, 2023, Frontiers in Immunology.

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds

Z. Sebestyén, S. Heijhuurs, J. Kuball, 2021, Journal for ImmunoTherapy of Cancer.

Disseminated nontuberculous mycobacterial infections after allogeneic hematopoietic stem cell transplantation: a risk-based strategy for early diagnosis.

R. Leguit, H. Wunderink, A. Bruns, 2023, Bone marrow transplantation.

Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia

J. Zwaginga, M. Huisman, J. G. van der Bom, 2021, European journal of haematology.

CRISPR screens decode cancer cell pathways that trigger γδ T cell detection

J. Pritchard, E. Adams, K. Hanspers, 2023, Nature.

γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia

D. Baarle, A. Marchant, B. Plachter, 2013, Leukemia.

Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor.

S. Strand, A. Martens, Marit M. van Buuren, 2011, Blood.

A novel bioinformatics pipeline for the identification of immune inhibitory receptors as potential therapeutic targets

M. Vlist, L. Meyaard, J. Kuball, 2023, bioRxiv.

Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP)

N. Knelange, R. de la Cámara, J. Hoogenboom, 2023, Bone Marrow Transplantation.

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit

B. Nuijen, Z. Sebestyén, J. Kuball, 2023, Immuno-oncology technology.

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

Annelisa M Cornel, F. Barneh, G. Kaspers, 2024, bioRxiv.